Tocilizumab
Anti–IL-6 receptor
- Response rate
- Initial response, loss of efficacy
- Onset
- Weeks
- Route
- SC or IV
- Line
- Alternative
- IgM effect
- Unknown
Evidence summary
IL-6 is elevated in Schnitzler syndrome, but a 9-patient open-label study (2024) showed initial clinical/biological response with subsequent loss of efficacy over time. May be considered for rare IL-1-refractory cases.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-6 | B-cell growth factor | Elevated | strong |